NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...

Full description

Bibliographic Details
Main Authors: Helene Cawston, Francois Bourhis, Jennifer Eriksson, Pierfrancesco Ruffo, Paolo D’Agostino, Marco Turini, Lee Schwartzberg, Alistair McGuire
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2017-03-01
Series:Drugs in Context
Subjects:
antiemetics
cost-effectiveness
medical oncology
meta-analysis
nausea
netupitant
palonosetron
quality of life
review literature
vomiting
Online Access:http://www.drugsincontext.com/nepa-a-new-fixed-combination-of-netupitant-and-palonosetron-is-a-cost-effective-intervention-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-the-uk/

Internet

http://www.drugsincontext.com/nepa-a-new-fixed-combination-of-netupitant-and-palonosetron-is-a-cost-effective-intervention-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-the-uk/

Similar Items